This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The global cancer immunotherapy pipeline continues to explode with nearly double the number of active targets in 2019 vs. only…
Article
4 years ago ●
3 mins read
Context. BLU-945 (Blueprint Medicines) is an oral EGFR mutant inhibitor being developed for treatment-resistant non-small-cell lung cancer (NSCLC). Although three…
molecule
1 year ago ●
5 mins read
Scientists from GlaxoSmithKline’s Stevenage site have an excellent article in J. Med. Chem. showing that cyclopropyl pyran (CPP) groups can…
Article
4 years ago ●
4 mins read
Context. SAGE-718 (Sage Therapeutics) is an oral N-methyl-d-aspartate receptor (NMDAR) Positive Allosteric Modulator (PAM) being developed for cognitive impairment in…
molecule
1 year ago ●
6 mins read
Modern hit-finding technologies are incredible. Dean Brown and Jonas Bostrom at AstraZeneca have a very nice review out summarizing the…
Article
5 years ago ●
10 mins read
Context. BI-4142 (Boehringer Ingelheim) is a HER2 exon 20 insertion mutant inhibitor being developed for non-small cell lung cancer (NSCLC).…
molecule
1 year ago ●
5 mins read
Load More
